Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis

Abstract

Antiangiogenetics (AAG) are drugs that are commonly used to treat a number of neoplasms, including renal cell carcinoma (RCC). They exert their activity by inhibiting the vascular endothelial growth factor pathway. Hypertension (HTN) represents one of the most common side effects secondary to AAG employment, and recent studies seem to suggest rising evidence of a possible relationship between AAG-related hypertension (AAG-HTN) and a better outcome for patients. The aim of this meta-analysis was to verify the hypothesis that AAG-HTN might represent a prognostic factor in advanced RCC. A total of 15 out of 434 studies were included, which explored the prognostic impact of HTN, and reported a hazard ratio and 95% confidence interval for overall survival (OS) and progression-free survival (PFS). AAG-HTN development was positively related to both OS and PFS, and all possible clinical implications and the potential role of AAG-HTN as a prognostic marker are discussed.

Keywords

Angiogenesis inhibitors Carcinoma renal cell Hypertension Survival Vascular endothelial growth factor A

Get full access to this article

View all access options for this article.

References

Gnarra

Tory

Weng

. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994 7 1 85–90.

Zhu

Stergiopoulos

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009 48 1 9–17.

Abdel-Rahman

Fouad

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol 2014 92 3 194–207.

Tan

Wang

Long

Chen

Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis. Exp Ther Med 2015 9 6 2275–2280.

Brinda

Viganego

Dolan

Fradley

Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. Curr Treat Options Cardiovasc Med 2016 18 5 33.

Facemire

Nixon

Griffiths

Hurwitz

Coffman

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009 54 3 652–658.

Lankhorst

Saleh

Danser

van den Meiracker

Etiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol 2015 217–13.

Greene

Tonellato

Lui

Lombard

Cowley

Jr Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989 256 1 Pt 2 H126–H131.

Chow

Gridley

Fraumeni

Jr Järvholm

Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000 343 18 1305–1311.

10.

Hurwitz

Douglas

Middleton

. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013 18 3 273–280.

11.

Hamnvik

Choueiri

Turchin

. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015 121 2 311–319.

12.

Moher

Shamseer

Clarke

et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015 4 1 1.

13.

US Department of Health and Human Services. National Institutes of Health National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.03 published June 14, 2010. http://theradex.com/downloads/CTCAE4.3codelist201007.pdf. Accessed March 6, 2017.

14.

US Department of Health and Human Services. National Institutes of Health National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 3.0, published March 31, 2003. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed March 6, 2017.

15.

The Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 5, 2016.

16.

Jadad

Moore

Carroll

. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 1 1–12.

17.

Cochrane. http://handbook.cochrane.org/training/cochrane-handbook.

18.

Egger

Davey

Smith G

Schneider

Minder

Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 315 7109 629–634.

19.

Duval

Tweedie

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000 56 2 455–463.

20.

Bono

Rautiola

Utriainen

Joensuu

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011 50 4 569–573.

21.

Donskov

Michaelson

Puzanov

. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer 2015 113 11 1571–1580.

22.

Goldstein

Rosenberg

Figlin

. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer 2016 5396–104.

23.

Izzedine

Derosa

Le Teuff

Albiges

Escudier

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015 26 6 1128–1133.

24.

Kucharz

Dumnicka

Kuzniewski

Kusnierz-Cabala

Herman

Krzemieniecki

Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Tumori 2015 101 5 555–559.

25.

Keizman

Gottfried

Ish-Shalom

. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014 19 1 51–60.

26.

Szmit

Langiewicz

Złnierek

. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2012 35 1 18–25.

27.

Miyake

Kuwada

Hori

. The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. BMC Res Notes 2016 9 1 79.

28.

Rini

Cohen

. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011 103 9 763–773.

29.

Motzer

Escudier

Tomczak

. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013 14 6 552–562.

30.

Nakano

Komatsu

Kubo

. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol 2013 43 10 1023–1029.

31.

Eechoute

van der Veldt

AAM

Oosting

. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012 92 4 503–510.

32.

Hamnvik

Choueiri

Turchin

. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015 121 2 311–319.

33.

Iacovelli

Verri

Cossu

Rocca M

. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anticancer Drugs 2017 28 2 206–212.

34.

Motzer

Bacik

Schwartz

. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004 22 3 454–463.

35.

Heng

Xie

Regan

. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009 27 34 5794–5799.

36.

Poprach

Pavlik

Melichar

et al; Czech Renal Cancer Cooperative Group. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012 23 12 3137–3143.

37.

Zheng

Wang

. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China. Medicine (Baltimore) 2015 94 49 e2222.

38.

Rini

Garrett

Poland

. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 2013 53 5 491–504.

39.

Derosa

Izzedine

Albiges

Escudier

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Oncol Rev 2016 10 2 298.

40.

Izzedine

Ederhy

Goldwasser

. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009 20 5 807–815.

41.

Maitland

Bakris

Black

. Cardiovascular Toxicities Panel, convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. J Natl Cancer Inst 2010 102596–604.

42.

Virani

Dent

Brezden-Masley

. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol 2016 32 7 831–841.

43.

Di Lorenzo

Autorino

Bruni

. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009 20 9 1535–1542.

44.

Azizi

Chedid

Oudard

Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008 358 1 95–97.